Gyre Therapeutics (NASDAQ:GYRE) Posts Quarterly Earnings Results, Misses Expectations By $0.06 EPS

Gyre Therapeutics (NASDAQ:GYRE) announced its quarterly earnings data on Friday. The company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.06), FiscalAI reports. The firm had revenue of $29.11 million during the quarter, compared to the consensus estimate of $26.49 million. Gyre Therapeutics had a negative net margin of 5.44% and a positive return on equity of 3.13%.

Gyre Therapeutics Stock Performance

Shares of Gyre Therapeutics stock traded up $0.27 on Friday, reaching $6.67. 67,603 shares of the company’s stock were exchanged, compared to its average volume of 52,226. The company has a market capitalization of $743.63 million, a P/E ratio of -74.10 and a beta of 1.92. Gyre Therapeutics has a 52 week low of $5.44 and a 52 week high of $9.42. The firm’s 50-day moving average is $6.25 and its two-hundred day moving average is $7.07.

Analyst Ratings Changes

GYRE has been the subject of a number of research reports. Zacks Research upgraded Gyre Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Monday, July 6th. Wall Street Zen lowered Gyre Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Finally, Weiss Ratings cut Gyre Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a report on Monday, May 11th. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Gyre Therapeutics presently has a consensus rating of “Hold” and an average target price of $17.00.

Insider Buying and Selling at Gyre Therapeutics

In related news, COO Weiguo Ye sold 12,820 shares of the company’s stock in a transaction that occurred on Thursday, May 21st. The stock was sold at an average price of $6.15, for a total transaction of $78,843.00. Following the transaction, the chief operating officer directly owned 700,000 shares of the company’s stock, valued at approximately $4,305,000. This represents a 1.80% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 9.50% of the company’s stock.

Hedge Funds Weigh In On Gyre Therapeutics

A number of hedge funds have recently bought and sold shares of GYRE. Geode Capital Management LLC increased its holdings in Gyre Therapeutics by 13.0% during the fourth quarter. Geode Capital Management LLC now owns 423,222 shares of the company’s stock worth $2,989,000 after buying an additional 48,602 shares during the last quarter. State Street Corp increased its stake in shares of Gyre Therapeutics by 10.7% during the 4th quarter. State Street Corp now owns 202,225 shares of the company’s stock worth $1,428,000 after purchasing an additional 19,472 shares during the last quarter. Charles Schwab Investment Management Inc. increased its stake in shares of Gyre Therapeutics by 37.1% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 169,158 shares of the company’s stock worth $1,194,000 after purchasing an additional 45,772 shares during the last quarter. Millennium Management LLC bought a new stake in shares of Gyre Therapeutics in the 3rd quarter worth approximately $267,000. Finally, Goldman Sachs Group Inc. raised its holdings in shares of Gyre Therapeutics by 72.5% in the 4th quarter. Goldman Sachs Group Inc. now owns 31,108 shares of the company’s stock worth $220,000 after purchasing an additional 13,074 shares during the period. 23.99% of the stock is owned by hedge funds and other institutional investors.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing small-molecule therapies that target lipid biology to treat a range of metabolic, inflammatory and neurodegenerative diseases. The company’s proprietary platform combines lipidomic profiling with drug discovery tools to identify compounds that selectively modulate membrane lipid composition and restore normal protein function in disease-relevant cells.

Gyre’s preclinical pipeline includes programs in nonalcoholic steatohepatitis (NASH), Alzheimer’s disease and autoimmune conditions, reflecting its strategy of applying a unified lipid-targeted approach across multiple therapeutic areas.